Luis Zuniga DNP, MSN, RN OCN

Interim Regional Director- West at Stemline Therapeutics

Luis Zuniga has extensive work experience in the healthcare industry, with a focus on oncology. Luis currently holds the position of Interim Regional Director - West and Medical Science Liaison at Stemline Therapeutics since August 2022. Prior to that, they worked as an Oncology Nurse Educator at Gilead Sciences from August 2021 to August 2022. Luis also served as a Multidisciplinary Nurse Coordinator at Stanford Health Care's Women's Cancer Center from November 2017 to December 2021. During their time at Takeda Oncology from September 2018 to August 2021, they worked as a Clinical Nurse Educator. Additionally, they held the role of Senior Clinical Coordinator at Genentech from January 2016 to September 2018. Earlier in their career, they worked as a Registered Nurse Oncology-Infusion at both Kaiser Permanente from September 2014 to January 2016 and Palo Alto Medical Foundation from April 2014 to September 2014. Luis'swork experience also includes being a Clinical Nurse specializing in Stem Cell Transplant and Cellular Therapy at MD Anderson Cancer Center from March 2013 to April 2014.

Luis Zuniga, DNP, MSN, RN, OCN has a Bachelor of Science (BS) degree in Registered Nursing/Registered Nurse from Samuel Merritt University. Luis also holds a Bachelor of Science (BS) degree in Business Administration and Management, General from DeVry University. In 2019, they completed their Master of Science (MS) degree in Nursing Science from Chamberlain University. Additionally, Luis Zuniga obtained their Doctorate in Nursing Practice from Chamberlain University in 2021. Luis also holds a certification as an Oncology Certified Nurse, although the institution and date of obtaining the certification are unknown.

Links

Previous companies

Kaiser Permanente logo
Genentech logo
Stanford Health Care logo
Gilead Sciences logo

Org chart

Timeline

  • Interim Regional Director- West

    May 1, 2023 - present

  • Medical Science Liaison

    August, 2022

View in org chart